Novartis improves its 2024 outlook for the third time with Cosentyx

Swiss drugmaker Novartis on Tuesday raised its 2024 profit forecast for the third time amid greater use of its prescription drugs such as psoriasis and arthritis drug Cosentyx.

Share This Post: